Zentalis Pharmaceuticals, Inc. (CIK: 0001725160) EDGAR, Information, Filings... CompaniesBIO.Com

Zentalis Pharmaceuticals, Inc.

Mailing address
1359 BROADWAY, SUITE 1710, NEW YORK, NY, 10018
Phone
(212) 433-3791
State location
New York
State of incorporation
N/A
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Zentalis Pharmaceuticals, Inc. (CIK: 0001725160) is an American company incorporated in the state of New York. Head office is located at 1359 BROADWAY, SUITE 1710, NEW YORK, New York, 10018. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Zentalis Pharmaceuticals, Inc. is a public company and trade via Over-The-Counter (OTC).

Old names:

Zentalis Pharmaceuticals, LLC from 2020-08-Jan to 2020-06-Apr
Zeno Pharma, LLC from 2017-19-Dec to 2019-05-Sep

Owner	Filings	Transaction Date	Type of Owner
HAUSMAN DIANA	0001563992	May-08-2023	director
Roth Iris	0001964808	Feb-13-2023	officer: Chief Operating Officer
Brownstein Carrie	0001894232	Oct-03-2022	officer: Chief Medical Officer
Skvarka Jan	0001838042	Sep-09-2022	director
Paul Andrea	0001863130	Aug-01-2022	officer: General Counsel
Kariuki Enoch	0001843119	Feb-09-2021	director
Pinto Alexis	0001819302	Aug-31-2020	officer: Chief Legal Officer
Blackwell Kimberly	0001816465	Jul-01-2020	director
VIKING GLOBAL INVESTORS LP	0001103804	Apr-03-2020	10 percent owner
HALVORSEN OLE ANDREAS	0001133006	Apr-03-2020	10 percent owner
SUN ANTHONY Y	0001377952	Apr-03-2020	director, officer: President & CEO
Matrix Capital Management Company, LP	0001410830	Apr-03-2020	director, 10 percent owner, other: See Remarks
GOEL DAVID E.	0001548144	Apr-03-2020	director, 10 percent owner
Gallagher Cam	0001557832	Apr-03-2020	director
Ott David C.	0001621842	Apr-03-2020	10 percent owner
Viking Global Opportunities Portfolio GP LLC	0001629472	Apr-03-2020	10 percent owner
Viking Global Opportunities GP LLC	0001629476	Apr-03-2020	10 percent owner
Viking Global Opportunities Illiquid Investments Sub-Master LP	0001629482	Apr-03-2020	10 percent owner
Shabet Rose Sharon	0001711393	Apr-03-2020	10 percent owner
Epperly Melissa B,	0001807359	Apr-03-2020	officer: Chief Financial Officer
Takhar Karan S.	0001807398	Apr-03-2020	director
Bunker Kevin D.	0001807484	Apr-03-2020	officer: Chief Operating Officer
Voliotis Dimitris	0001807910	Apr-03-2020	officer: SVP, Clinical Development
Recurium Equity, LLC	0001808095	Apr-03-2020	10 percent owner
Johnson David Michael	0001808098	Apr-03-2020	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Zentalis Pharmaceuticals, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001808098-26-000003 ( Act) Size: 0 KB	Jun-18-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001838042-26-000003 ( Act) Size: 0 KB	Jun-18-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001701440-26-000004 ( Act) Size: 0 KB	Jun-18-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001843119-26-000003 ( Act) Size: 0 KB	Jun-18-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001356256-26-000005 ( Act) Size: 0 KB	Jun-18-2026
8-K	Document	Current report filing Acc-no: 0001725160-26-000052 (34 Act) Size: KB	Jun-18-2026	001-39263 261102436
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0002018966-26-000005 ( Act) Size: 0 KB	May-27-2026
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0002018966-26-000004 ( Act) Size: 0 KB	May-27-2026
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001725160-26-000050 (34 Act) Size: KB	May-27-2026	001-39263 261026203
8-K	Document	Current report filing Acc-no: 0001725160-26-000049 (34 Act) Size: KB	May-27-2026	001-39263 261026183
8-K	Document	Current report filing Acc-no: 0001725160-26-000045 (34 Act) Size: KB	May-21-2026	001-39263 261010026
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001725160-26-000042 (34 Act) Size: KB	May-12-2026	001-39263 26968639
8-K	Document	Current report filing Acc-no: 0001725160-26-000041 (34 Act) Size: KB	May-12-2026	001-39263 26968568
8-K	Document	Current report filing Acc-no: 0001725160-26-000033 (34 Act) Size: KB	May-05-2026	001-39263 26940514
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001725160-26-000028 (34 Act) Size: KB	Apr-30-2026	001-39263 26925329
DEF 14A	Document	Definitive proxy statements Acc-no: 0001725160-26-000027 (34 Act) Size: KB	Apr-30-2026	001-39263 26925099
ARS	Document	Annual report to security holders Acc-no: 0001725160-26-000026 (34 Act) Size: KB	Apr-30-2026	001-39263 26924932
8-K	Document	Current report filing Acc-no: 0001725160-26-000020 (34 Act) Size: KB	Apr-17-2026	001-39263 26871172
8-K	Document	Current report filing Acc-no: 0001725160-26-000017 (34 Act) Size: KB	Apr-09-2026	001-39263 26849864
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0001725160-26-000014 (34 Act) Size: KB	Mar-26-2026	001-39263 26799017

Recent 20 filings. View all Zentalis Pharmaceuticals, Inc. filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Zentalis Pharmaceuticals, Inc. overview
Zentalis Pharmaceuticals, Inc. job
Zentalis Pharmaceuticals, Inc. stock
Zentalis Pharmaceuticals, Inc. ownership
Zentalis Pharmaceuticals, Inc. CEO
Zentalis Pharmaceuticals, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.